CO6290704A2 - Virus de la estomatitis vesicular (vsv) atenuado y geneticamente modificado y composiciones inmunogenicas que lo contienen. - Google Patents
Virus de la estomatitis vesicular (vsv) atenuado y geneticamente modificado y composiciones inmunogenicas que lo contienen.Info
- Publication number
- CO6290704A2 CO6290704A2 CO10074482A CO10074482A CO6290704A2 CO 6290704 A2 CO6290704 A2 CO 6290704A2 CO 10074482 A CO10074482 A CO 10074482A CO 10074482 A CO10074482 A CO 10074482A CO 6290704 A2 CO6290704 A2 CO 6290704A2
- Authority
- CO
- Colombia
- Prior art keywords
- vsv
- immunogenic compositions
- genetically modified
- vesicular stomatitis
- attentioned
- Prior art date
Links
- 241000711975 Vesicular stomatitis virus Species 0.000 title abstract 6
- 230000002163 immunogen Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002238 attenuated effect Effects 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/04—Seven-membered rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
- C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
- C12N2760/20264—Methods of inactivation or attenuation by serial passage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con métodos para generar cepas genéticamente modificadas y atenuadas del virus de la estomatitis vesicular (VSV) para uso en la preparación de composiciones inmunogénicas. Más particularmente, la invención se relaciona con la identificación de modificaciones genéticas particulares del VSV atenuado que den como resultado un rendimiento creciente del virus y un incremento en la estabilidad del virus atenuado para la preparación de las composiciones inmunogénicas. También se describen los métodos para propagación del cultivo celular y el uso en producción a gran escala del VSV.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1586807P | 2007-12-21 | 2007-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6290704A2 true CO6290704A2 (es) | 2011-06-20 |
Family
ID=40791563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10074482A CO6290704A2 (es) | 2007-12-21 | 2010-06-21 | Virus de la estomatitis vesicular (vsv) atenuado y geneticamente modificado y composiciones inmunogenicas que lo contienen. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20090175906A1 (es) |
EP (1) | EP2224952A2 (es) |
JP (1) | JP2011507523A (es) |
KR (1) | KR20110004354A (es) |
CN (1) | CN101981182A (es) |
AR (1) | AR069883A1 (es) |
AU (1) | AU2008340319A1 (es) |
BR (1) | BRPI0821558A2 (es) |
CA (1) | CA2710350A1 (es) |
CL (1) | CL2008003794A1 (es) |
CO (1) | CO6290704A2 (es) |
IL (1) | IL206462A0 (es) |
PE (1) | PE20091104A1 (es) |
RU (1) | RU2010124788A (es) |
TW (1) | TW200932259A (es) |
WO (1) | WO2009082664A2 (es) |
ZA (1) | ZA201005182B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8481297B2 (en) * | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
WO2011032003A1 (en) | 2009-09-10 | 2011-03-17 | Yale University | Immunization to reduce neurotoxicity during treatment with cytolytic viruses |
WO2011056993A1 (en) | 2009-11-04 | 2011-05-12 | Yale University | Compositions and methods for treating cancer with attenuated oncolytic viruses |
KR20120068647A (ko) * | 2010-12-18 | 2012-06-27 | 아이진 주식회사 | 개선된 면역반응을 유도하는 백신 |
US9402891B2 (en) | 2011-06-08 | 2016-08-02 | Ohio State Innovation Foundation | Norovirus immunogens and related materials and methods |
US10179154B2 (en) | 2013-11-22 | 2019-01-15 | Yale University | Chimeric VSV virus compositions and methods of use thereof for treatment of cancer |
GB201614050D0 (en) * | 2016-08-17 | 2016-09-28 | Glaxosmithkline Ip Dev Ltd | Method for purifying viral vectors |
WO2018226506A1 (en) * | 2017-06-05 | 2018-12-13 | Arizona Board Of Regents On Behalf Of Arizona State University | Reducing the toxicity of agrobacterium endotoxin |
IL274444B1 (en) * | 2017-11-06 | 2024-02-01 | Rapt Therapeutics Inc | Chemokine receptor modulators for the treatment of Epstein-Barr virus-positive cancer |
CN110317832B (zh) * | 2018-03-28 | 2022-07-05 | 西比曼生物科技(香港)有限公司 | Gmp级规模化制备重组慢病毒载体的纯化制剂的方法 |
CN110317791A (zh) | 2018-03-29 | 2019-10-11 | 西比曼生物科技(香港)有限公司 | Gmp级无血清悬浮细胞大规模生产慢病毒的方法 |
CN110577585A (zh) * | 2018-06-07 | 2019-12-17 | 中国医学科学院基础医学研究所 | 水泡型口炎病毒包膜糖蛋白变体及其构建方法和应用 |
EP3823654B1 (en) | 2018-07-17 | 2024-02-14 | Yale University | Methods for treatment of cancer using chikungunya-vsv chimeric virus |
WO2020029274A1 (zh) * | 2018-08-10 | 2020-02-13 | 苏州奥特铭医药科技有限公司 | 一种减毒棒状病毒的制备方法及应用 |
CN110305850A (zh) * | 2019-05-15 | 2019-10-08 | 苏州奥特铭医药科技有限公司 | 一种利用293细胞生产制备溶瘤病毒的方法 |
JP2023527577A (ja) * | 2020-06-03 | 2023-06-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | CD80細胞外ドメインFc融合タンパク質をコードするリコンビナントラブドウイルス |
WO2022092779A1 (ko) * | 2020-10-29 | 2022-05-05 | 에스케이바이오사이언스 주식회사 | 사스-코로나바이러스-2 항원 물질을 포함하는 바이럴 벡터 및 이의 이용 |
WO2023221937A1 (zh) * | 2022-05-16 | 2023-11-23 | 上海行深生物科技有限公司 | 递送自复制rna分子的方法 |
WO2024056106A1 (zh) * | 2022-09-16 | 2024-03-21 | 中国科学院广州生物医药与健康研究院 | 一种节段化的水泡性口炎病毒载体及其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708871A (en) * | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
SE8405493D0 (sv) * | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5571515A (en) * | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0702085B2 (en) * | 1994-07-18 | 2010-01-13 | Conzelmann, Karl-Klaus, Prof. Dr. | Recombinant infectious non-segmented negative strand RNA virus |
US7153510B1 (en) * | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
US6596529B1 (en) * | 1997-05-02 | 2003-07-22 | Uab Research Foundation | Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof |
US6113918A (en) * | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6673572B2 (en) * | 1998-06-03 | 2004-01-06 | Wyeth Holdings Corporation | Methods for rescue of RNA viruses |
CA2386920C (en) * | 1999-09-17 | 2012-01-24 | Pro-Virus, Inc. | Oncolytic virus |
CN1871355B (zh) * | 2003-06-09 | 2011-12-14 | 惠氏 | 从cDNA中回收非节段性负链RNA病毒的改进方法 |
BRPI0509683A8 (pt) * | 2004-04-09 | 2015-12-22 | Wyeth Corp | Vírus de estomatite vesicular geneticamente modificado, vetor de vírus da estomatite vesicular geneticamente modificado, composição imunogênica, e, métodos para imunizar um hospedeiro mamífero contra infecção bacteriana e contra infecção viral |
PL2007883T3 (pl) * | 2006-04-20 | 2012-07-31 | Wyeth Llc | Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej |
-
2008
- 2008-12-18 KR KR1020107016259A patent/KR20110004354A/ko not_active Application Discontinuation
- 2008-12-18 CN CN200880127362XA patent/CN101981182A/zh active Pending
- 2008-12-18 RU RU2010124788/10A patent/RU2010124788A/ru not_active Application Discontinuation
- 2008-12-18 JP JP2010539785A patent/JP2011507523A/ja not_active Withdrawn
- 2008-12-18 PE PE2008002112A patent/PE20091104A1/es not_active Application Discontinuation
- 2008-12-18 CA CA2710350A patent/CA2710350A1/en not_active Abandoned
- 2008-12-18 CL CL2008003794A patent/CL2008003794A1/es unknown
- 2008-12-18 BR BRPI0821558A patent/BRPI0821558A2/pt not_active Application Discontinuation
- 2008-12-18 US US12/338,367 patent/US20090175906A1/en not_active Abandoned
- 2008-12-18 WO PCT/US2008/087375 patent/WO2009082664A2/en active Application Filing
- 2008-12-18 AU AU2008340319A patent/AU2008340319A1/en not_active Abandoned
- 2008-12-18 EP EP08865185A patent/EP2224952A2/en not_active Withdrawn
- 2008-12-19 AR ARP080105636A patent/AR069883A1/es not_active Application Discontinuation
- 2008-12-19 TW TW097149975A patent/TW200932259A/zh unknown
-
2010
- 2010-06-17 IL IL206462A patent/IL206462A0/en unknown
- 2010-06-21 CO CO10074482A patent/CO6290704A2/es not_active Application Discontinuation
- 2010-07-20 ZA ZA2010/05182A patent/ZA201005182B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PE20091104A1 (es) | 2009-07-18 |
EP2224952A2 (en) | 2010-09-08 |
CA2710350A1 (en) | 2009-07-02 |
AR069883A1 (es) | 2010-02-24 |
AU2008340319A1 (en) | 2009-07-02 |
RU2010124788A (ru) | 2012-01-27 |
ZA201005182B (en) | 2011-05-25 |
JP2011507523A (ja) | 2011-03-10 |
BRPI0821558A2 (pt) | 2015-11-03 |
WO2009082664A8 (en) | 2009-09-17 |
CL2008003794A1 (es) | 2009-03-20 |
IL206462A0 (en) | 2010-12-30 |
KR20110004354A (ko) | 2011-01-13 |
TW200932259A (en) | 2009-08-01 |
WO2009082664A3 (en) | 2009-11-26 |
CN101981182A (zh) | 2011-02-23 |
US20090175906A1 (en) | 2009-07-09 |
WO2009082664A2 (en) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6290704A2 (es) | Virus de la estomatitis vesicular (vsv) atenuado y geneticamente modificado y composiciones inmunogenicas que lo contienen. | |
DOP2022000152A (es) | Vacunas de arn contra el coronavirus | |
CL2008003020A1 (es) | Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado, que comprende generar celulas que expresan la proteina g de la vsv a partir de un gen vsv optimizado, infectar dichas celulas con el vsv atenuado, y recuperar los virus dle cultivo; composicion que comprende al virus atenuado y kit para producir el virus. | |
CY1121225T1 (el) | Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις | |
CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
UY37563A (es) | Aislados de bacillus y usos de los mismos | |
MX2019007840A (es) | Celulas asesinas naturales modificadas geneticamente. | |
AR059772A1 (es) | Composiciones que incuyen hemaglutinina metodos de elaboracion y metodos de uso de las mismas | |
CO6761348A2 (es) | Compuestos antivirales | |
CL2010001407A1 (es) | Compuestos derivados de purina y pirimidina sustituidos; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar enfermedades virales tales como hepatitis c, dengue, fiebre amarilla, polio, hepatitis a, entre otras. | |
AR109564A1 (es) | Métodos para producir enterovirus c para la producción de vacunas | |
ECSP10010206A (es) | Inhibidores de la replicación del virus de la imunodeficiencia humana | |
GT200800095A (es) | Nucleosidos antivirales | |
CO6361922A2 (es) | Inhibidores del virus de la hepatitis c | |
BR112013002811A8 (pt) | meios básicos simplificados para cultura celular pluripotente de humano | |
AR085507A1 (es) | Animales modificados geneticamente y metodos para su obtencion | |
AR065100A1 (es) | Plantas con rasgos relacionados con el rendimiento mejorado y un metodo para producirlas | |
UY33654A (es) | Gen rf4 restaurador de esterilidad masculina citoplasmática (cms) tipo c en el maíz, marcadores mol eculares y uso de los mismos | |
MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
ECSP13012438A (es) | Proceso para preparar compuestos antivirales | |
SV2011003943A (es) | Procedimiento para la preparacion de depsipeptidos ciclicos, opticamente activos, con 24 atomos anulares, que contienen acido lactico y acido fenil lactico, usando cepas fungicas de la especie rosellinia y de otros xilariaceos | |
CO2018001264A2 (es) | Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos | |
CL2010000774A1 (es) | Medio para el cultivo de celulas de mamiferos que comprende ademas de los nutrientes habituales de los medios de cultivo basales para cultivo de celulas de mamiferos, sobrenadante de la fraccion ii+iii del plasma humano segun el metodo de cohn; procedimiento de preparacion; y su uso. | |
AR069885A1 (es) | Metodos para producir el virus de estomatitis vesicular (vsv) atenuado en un cultivo celular y para mejorar el empaque del vsv de propagacion defectuosa, composicion inmunogenica, celula aislada y secuencia de control transcripcional | |
GT201100241A (es) | Proceso para preparar compuestos antivirales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |